Sign Out
Pregnancy: There are no or limited amount of data from the use of micronised purified flavonoid fraction in pregnant women.
Experimental studies performed in animals have not revealed a teratogenic effect (see Pharmacology: Toxicology: Preclinical safety data under Actions).
As a precautionary measure, it is preferable to avoid the use of DAFLON during pregnancy.
Breastfeeding: It is unknown whether the active substance/metabolites are excreted in human milk.
A risk to the newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from DAFLON therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: Reproductive toxicity studies have shown no effects on female and male rats
